Exclusive Summary

• - Patent protection expired globally; market is highly genericized with steady demand for 250 mg capsules in the Americas and beyond.
• - PBC is the core indication with an estimated 0.5–2.0 million patients worldwide; UDCA is first-line and often lifelong therapy.
• - FDA cGMP-certified manufacturing supports entry into stringent/reference markets and participation in public tenders.
• - Generics typically offer 60–90% cost savings versus originators, enabling switches and access expansion, especially in emerging markets.
• - Differentiation relies on quality consistency, reliable supply, and dossier readiness rather than first-to-market timing.